Literature DB >> 28033222

Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key?

Ingo Janssen1, Katherine I Wolf, Chan H Chui, Corina M Millo, Karel Pacak.   

Abstract

Pheochromocytomas/paragangliomas are somatostatin receptor 2-overexpressing tumors. Ga-DOTA-peptide imaging has recently shown excellent results in the detection of metastatic lesions in these tumors. However, currently used Ga-DOTA peptides show different somatostatin receptor affinities. Here, we report the remarkable differences in a patient who was imaged with Ga-DOTANOC and Ga-DOTATATE PET/CT within a 7-month period. The patient presented with a nearly negative Ga-DOTANOC PET/CT scan, whereas on Ga-DOTATATE PET/CT, multiple highly positive lesions were identified.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28033222      PMCID: PMC5290153          DOI: 10.1097/RLU.0000000000001504

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  8 in total

1.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

2.  'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs.

Authors:  Sandip Basu; Amit Abhyankar; Purushottam Kand; Rakesh Kumar; Ramesh Asopa; Mysore Govinda Ramakrishna Rajan; Uday Nayak; Hemant Shimpi; Tapas Das; Meera Venkatesh; Sudipta Chakrabarty; Sharmila Banerjee
Journal:  Nucl Med Commun       Date:  2011-07       Impact factor: 1.690

3.  Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Authors:  Damian Wild; Jamshed B Bomanji; Pascal Benkert; Helmut Maecke; Peter J Ell; Jean Claude Reubi; Martyn E Caplin
Journal:  J Nucl Med       Date:  2013-01-07       Impact factor: 10.057

4.  Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.

Authors:  Marianne S Elston; Goswin Y Meyer-Rochow; Helen M Conaglen; Adele Clarkson; Roderick J Clifton-Bligh; John V Conaglen; Anthony J Gill
Journal:  Hum Pathol       Date:  2014-12-02       Impact factor: 3.466

5.  Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Eur J Nucl Med       Date:  2001-07

6.  Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Clemens Decristoforo; Ahmet Araman; Yıldız Ozsoy; Ilhami Uslu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-20       Impact factor: 9.236

7.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

8.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Authors:  P Antunes; M Ginj; H Zhang; B Waser; R P Baum; J C Reubi; H Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-16       Impact factor: 10.057

  8 in total
  1 in total

Review 1.  Imaging of neuroendocrine neoplasms of the male GU tract.

Authors:  Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma
Journal:  Abdom Radiol (NY)       Date:  2022-04-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.